AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-19
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(0) · ALS(1) · Parkinson's(1) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
- Abstract
This study examines whether adding waveform-derived information-theoretic descriptors to Mel-spectrogram inputs offers a measurable benefit for five-class amyotrophic lateral sclerosis (ALS) dysarthria speech-status classification. The primary evidence is a study-specific, five-fold recording-level CNN comparison: Mel-only accuracy is 0.926±0.012, while historical fusion accuracy is 0.927±0.008. A distinct CNN fusion verification/reproduction run, with traced propagation of the Mel input and all 17 information-theoretic descriptors, reports accuracy of 0.927±0.010; it does not retrospectively verify the archived historical input tensors. Thus, the available comparisons show only a small numerical change, not a demonstrated general advantage of fusion. Complementary analyses include a direct participant-disjoint CNN comparison, a fixed-duration CNN comparison, and seed, duration, padding, and task-specific controls. In the participant-disjoint comparison, Mel-only and fusion achieve accuracies of 0.820 and 0.823, respectively, whereas under the fixed-duration condition they achieve 0.914 and 0.915. These distinct result series show similarly small numerical differences between Mel-only and fusion under the additional evaluation conditions. They do not establish a matched estimate of the effect of participant overlap or a statistically reliable advantage of feature fusion. Source-code auditing identifies discrepancies between an available implementation and the documented score-producing benchmark, without establishing that leakage occurred in the latter. Missing run-linked records, class imbalance, and the absence of external validation constrain conclusions to the evaluated speech-processing pipelines. Class 4 represents ALS without dysarthria, not early bulbar disease detection.
Journal IF-equivalent: 5.5 (OpenAlex 2-year mean citedness, value as of 2026-11-17, retrieved 2026-11-19; not the official Clarivate IF)Reference: Taparugssanagorn A, Caputo S, Borghini G, Mucchi L. Speech-Based Dysarthria Severity Classification in Amyotrophic Lateral Sclerosis: A Controlled Deep Learning Benchmark. Electronics. 2026 Nov 17;15(22):5362. doi:10.3390/electronics15225362.Checked: Abstract only
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Optical coherence tomography (OCT) images have emerged as a promising means for PD recognition. However, constructing a precise DNN-based PD recognition model requires a large number of OCT images and expensive computational resources. This paper aims to transfer pre-trained visual foundation models (VFMs) with the aid of the adapter learning paradigm to recognize PD from OCT images, by adding only a few trainable parameters. We propose a novel VFM-Adapter framework for automatic OCT-based PD recognition based on the adapter learning paradigm. To be specific, we introduce three lightweight adapters: global adapter, local adapter, and token-wise adapter, to effectively leverage the transferability of feature representations from VFMs to OCT images, for equipping VFMs with strong PD recognition capability. Our VFM-Adapter achieves an accuracy of 77.66%, sensitivity of 78.01%, specificity of 77.31%, F1-score of 77.93%, and precision of 79.58%. It outperforms state-of-the-art deep neural networks, such as convolutional neural networks (CNNs), attention-based CNNs, and vision transformers by updating only a small number of parameters. Extensive ablation studies further demonstrated the effectiveness of each adapter. The proposed VFM-Adapter provides an effective yet parameter-efficient transfer learning framework for OCT-based PD recognition. By substantially finetuning the small number of trainable parameters while maintaining competitive PD performance, the proposed framework offers a promising altetnative for automated PD screening in real-world diagnosis scenarios. Not applicable.
Journal IF-equivalent: 9.7 (OpenAlex 2-year mean citedness, value as of 2026-11-17, retrieved 2026-11-19; not the official Clarivate IF)Reference: Zhang J, Wang T, Shao D, Yang Y, He J, Zheng M, et al. Visual foundation models with adapter learning for Parkinson’s disease recognition based on OCT images. BMC Med Inform Decis Mak. 2026 Nov 17 [Epub ahead of print]. doi:10.1186/s12911-026-03979-z.Checked: Abstract only
See all 1 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
- Abstract
Ex vivo 9.4T T2*-weighted MRI (75 µm isotropic, magnitude and phase) of human spinal cord samples from 26 donors (18 multiple sclerosis, 4 progressive multifocal leukoencephalopathy, 2 cerebrovascular disease, 2 amyotrophic lateral sclerosis), organized in BIDS. Derivatives include sparse 2D manual segmentations of spinal cord, gray matter and lesions (derivatives/labels_2d), dense 3D pseudo-labels predicted slice-wise by a 2D model (derivatives/pseudo_labels_3d), and one dense manually verified 3D label (derivatives/labels_3d). This dataset accompanies Hoareau et al., "Optimization in Sparse 2D to Dense 3D Weakly Supervised Learning: Application to Multi-Label Segmentation of Large ex vivo MRI Data", Machine Learning for Biomedical Imaging (MELBA). Code and models: https://github.com/ivadomed/model_seg_sc-gm-lesion_human_ms_exvivo_t2star
Journal IF-equivalent: 1.2 (OpenAlex 2-year mean citedness, value as of 2026-11-17, retrieved 2026-11-19; not the official Clarivate IF)Reference: [No authors listed]. Ex vivo 9.4T T2*-weighted MRI of the human spinal cord with spinal cord, gray matter and lesion segmentations (MS, PML, ALS, CVD). Borealis. [Epub ahead of print]. doi:10.5683/sp4/p9zciw.Checked: Abstract only
See all 1 Multiple sclerosis papers →
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.